ZYUS Life Sciences Corporation (TSXV:ZYUS)

Market Cap	48.31M +1.3%
Revenue (ttm)	374.00K -22.6%
Net Income	-19.46M
EPS	-0.25
Shares Out	80.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,122
Open	0.6000
Previous Close	0.6000
Day's Range	0.6000 - 0.6000
52-Week Range	0.3950 - 0.7500
Beta	0.46
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Sas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: ZYUS

Financial Performance

In 2025, ZYUS Life Sciences's revenue was 405,000, a decrease of -15.80% compared to the previous year's 481,000. Losses were -21.73 million, -35.72% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 30, 2026

Data Sources Report a data error